Company
Botanix Pharmaceuticals Ltd
ASX:BOT
Botanix Pharmaceuticals Ltd (ASX:BOT) is a clinical-stage synthetic cannabinoid company committed to the development of pharmaceutical products. The company is developing a pipeline of product candidates that leverages the antimicrobial properties of cannabinoids.
19 stories
Botanix Pharmaceuticals receives approval for BTX 1702 Rosacea clinical study
The clinical study will be a randomised, double-blind, vehicle-controlled study in patients suffering from moderate to severe papulopustular rosacea to investigate the safety and tolerability of BTX 1702 over an 8-week treatment period.
Botanix Pharmaceuticals has antimicrobial data published in leading peer-reviewed research journal
The research article represents the culmination of research collaborations involving leading antimicrobial researchers across the world.
Botanix Pharmaceuticals completes BTX 1801 antimicrobial Phase 2a clinical study
The company is developing a pipeline of product candidates that leverage the antimicrobial properties of cannabinoids with a BTX 1801 Phase 2a study for the prevention of surgical site infections well advanced.
Botanix Pharmaceuticals shares surge after BTX 1801 gets US FDA’s Qualified Infectious Disease Product status
This is a significant milestone for Botanix as BTX 1801 is the first cannabinoid-based program to receive the designation globally and represents a strong endorsement of Botanix’s data.
Botanix Pharmaceuticals treats first patient in phase 1b psoriasis study
Uniquely designed patient study which allows the comparison of multiple drugs on the same patient at the same time.
Botanix Pharmaceuticals concludes successful atopic dermatitis study
BTX 1204 was effective at reducing the key signs and symptoms of atopic dermatitis.
Botanix Pharmaceuticals advances eczema study faster than expected
The company is developing BTX 1204, a new treatment for eczema.
Botanix Pharmaceuticals attracts $15 million for unique acne product
Funds raised will be used to accelerate clinical development of its lead acne product.
Botanix Pharmaceuticals’ shares ride higher following successful acne study
Large reductions in acne lesions observed after 4 weeks of treatment.
Botanix Pharmaceuticals to commence acne treatment patient study
The company’s BTX 1503 is a topical treatment for moderate to severe acne.
Botanix Pharmaceuticals' shares halted pending ethics approval update
The halt will remain in place until Monday 21st August 2017.
Botanix Pharmaceuticals Ltd crosses a milestone in product development
The company will now commence a follow up acne patient pilot study.
Botanix Pharmaceuticals to reveal clinical results
The halt will remain in place until Tuesday 4th July 2017.
Botanix Pharmaceuticals raises $7.4M to advance product development
The company has developed a transdermal drug delivery technology.
Botanix Pharmaceuticals begins first clinical study of acne product
The treatment utilises synthetic cannabidiol as the active ingredient.
Botanix Pharmaceuticals raising $7.4M for synthetic cannabidiol products
Starting a clinical study of synthetic cannabidiol for skin disease.
Botanix Pharmaceuticals gets approval for synthetic cannabidiol trial
First-ever trial of synthetic cannabidiol for a skin disease.
Botanix Pharmaceuticals Ltd attracts investment from its own chairman
Botanix listed on the ASX in July 2016 by way of reverse takeover.